A recent study has demonstrated that a single dose of psilocybin can significantly alleviate symptoms of depression within days, with effects lasting over three months when compared to a placebo. The research, detailed in the journal JAMA Network Open, involved 35 participants experiencing recurring depression.
Participants were randomly assigned to receive either psilocybin or a placebo. The placebo, which was vitamin B3, imitated some of psilocybin’s physical effects, such as temporary skin flushing. Both groups were provided with psychological support before, during, and after the dosing.
While many studies have investigated psilocybin’s effectiveness for treatment-resistant depression, this study aimed to determine its impact on more common forms of depression.
Notably, within just eight days, those who took psilocybin exhibited significant mood improvements. By the end of a six-week follow-up, over half of the psilocybin group no longer met the criteria for depression, whereas only one person in the placebo group showed similar improvement.
The treatment was generally well-received, though two participants did experience prolonged anxiety. Over the course of a year, the study tracked how long the benefits endured, finding that the positive effects in the psilocybin group persisted for over three months based on self-assessments.
After this period, the difference between the psilocybin and placebo groups started to diminish as the placebo group also showed improvement. This pattern is common, as depression symptoms often fluctuate and may improve over time even without treatment.
During the follow-up period, just over a third of participants in both groups began taking antidepressant medication, typically around four months after the trial began.
The problem of blinding
A significant challenge in the study was maintaining “blinding,” or keeping participants unaware of whether they received psilocybin or a placebo. Despite using identical-looking capsules and an active placebo, nearly all participants guessed their treatment correctly due to psilocybin’s distinct and noticeable effects.
This awareness is crucial because expectations can influence outcomes. Participants who experienced strong effects from psilocybin might have had heightened hopes for the treatment’s efficacy. Conversely, those receiving a placebo and noticing no effects could feel disappointed, which might affect their later self-reported mood and symptoms.
Participation in trials generally boosts mood due to the attention, support, and regular follow-up provided, even for those in the placebo group. However, research indicates that placebo recipients in psilocybin studies often show less improvement than those in traditional antidepressant trials, a trend observed in this study as well.
If placebo groups in psilocybin studies do not improve in expected ways, the perceived effectiveness of psilocybin can appear exaggerated. Overall, the findings suggest psilocybin could offer a quick and enduring treatment for depression, beneficial for both common and treatment-resistant forms of the condition, potentially significantly impacting patient care.
Related: Single Dose of DMT Rapidly Reduces Symptoms of Major Depression
Nonetheless, the study highlights a critical challenge: distinguishing the drug’s biological effects from the substantial influence of expectations and experiences. Resolving this issue is essential for determining psilocybin’s role in future mental health treatments.
Hampus Yngwe, PhD Candidate, Psychiatry, Karolinska Institutet and Johan Lundberg, Adjunct Professor, Psychiatry, Karolinska Institutet
This article is republished from The Conversation under a Creative Commons license. Read the original article.
